LinkedIn IconTwitter Icon
14-16 November 2017
The Westin Grand Munich, Germany

News & More

Here you will find the most up-to-date news and press releases
in the immune checkpoint inhibitor space.

 

Epivax_TN EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology

View here

 

 

Fierce_TN Merck, looking to build on cancer success, buys I-O biotech Rigontec

View here

Immunotherapy drug extends survival for kidneyImmunotherapy drug extends survival for kidney cancer patients

View here

Seattle Genetics Announces Initiation of Phase 1Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin)in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma

View here

Keytruda Now NHS-Approved in England for Melanoma

Keytruda Now NHS-Approved in England for Melanoma

 View here

New Cohorts from CheckMate -012 Assess Optimal Dosing

New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

 View here

Groundbreaking cancer drug given NHS approval

Groundbreaking cancer drug given NHS approval

 View here

AstraZeneca, Peregrine to Partner on Immuno-Oncology Combo Trial

AstraZeneca, Peregrine to Partner on Immuno-Oncology Combo Trial

 View here

Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Lung Cancer

Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Lung Cancer

 View here

European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

 View here

European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer

European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer

 View here

UPDATED: Bristol-Myers flags early success for PhIII Opdivo study in kidney cancer

UPDATED: Bristol-Myers flags early success for PhIII Opdivo study in kidney cancer

 View here

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab)

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients

 View here

Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

 View here

ASCO: Test May Identify Best Patients for Immunotherapy

ASCO: Test May Identify Best Patients for Immunotherapy

 View here

Peregrine Pharma (PPHM) Enters PS-Targeting Antibody Program Collaboration with MSK

Peregrine Pharma (PPHM) Enters PS-Targeting Antibody Program Collaboration with MSK

 View here

AstraZeneca, Lilly to Study Immuno-Oncology Combination

AstraZeneca, Lilly to Study Immuno-Oncology Combination

 View here

ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma

ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma

 View here

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

 View here

AZ seals pr 28.04

AZ seals immuno-oncology deals as Q1 sales, earnings, slip

 View here

bms business pr 28.04

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

 View here

new therapy pr 28.04

New therapy to tackle treatment-resistant cancers

 View here

argenx pr 28.04

arGEN-X announces publication on therapeutic potential of antibody ARGX-115 in cancer immunotherapy

 View here

Celgene 24.04

Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers

 View here

Gen news 23.04

Astellas, Potenza Partner on Cancer Immunotherapies

 View here

aacr pr

Stepping into the Era of Combination Cancer Therapies, Part 1: Combining Immunotherapies

 View here

peregrine aacr pr

Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals’ Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer

 View here

business wire 20.04

cCAM Biotherapeutics Announces Initiation of Phase 1 Trial of CM-24, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy

 View here

onelive

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

View here

checkmate

CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

View here

biotech 15.04

Roche hustles its PD-L1 ‘breakthrough’ star into 11 late-stage trials

View here

oncolytics press thumb 27.03.15

Oncolytics Biotech® Inc. Presents at the 2015 Immune Checkpoint Inhibitors Meeting

View here

biopharm press 23.03.15

Keytruda Use Allowed Sans EMA Approval

View here

business wire 18.03.15

Enumeral to Present Corporate and Program Overview at March Conferences

View here

fierce press 17.03.15

Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A

View here

fierce thumb opdivo

Opdivo’s survival benefit inspired FDA to act fast on NSCLC approval: Pazdur

View here

CRI press release thumbBig News: FDA Approves Opdivo (Nivolumab) for Lung Cancer

View here

gen press relases thumb

BMS Deals Add to Its Immuno-Oncology Portfolio

View here

seattle genetics press release

Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors

View here

oncolytics press thumb

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer

View here

peregrine thumb press release

Newly Presented Data Shows That Peregrine Pharmaceuticals’ PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma

View here

Roches anti PDL1 FDA 2 feb press release

Roche’s anti-PDL1 receives FDA breakthrough therapy designation to treat NSCLC

View here

cCam Biotherapeutics article thumbcCAM Biotherapeutics Receives FDA Approval to Initiate Phase 1 Trial for CM-24, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy

View here

Fierce newsNew biotech pairs up with Amgen on a cancer immunotherapy

View here

pharmacy choice thumbcCAM Biotherapeutics Secures FDA OK to Initiate Phase 1 Trial for CM- 24

View here

 

BMS press release thumb

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

View here

BMS press release thumb 2

Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors

View here

Cancer Cell Article thumbnail

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

View here

 

Fierce Biotech pfizer article

Pfizer powers into immuno-oncology with $2.85B R&D  pact with Merck KGaA

View here

News Fierce Biotech article

Pfizer strikes another immunotherapy deal to widen its oncology pipeline

View here

 

Cancer’s Super-Survivors

News Cancer's super-survivorsHow the Promise of Immunotherapy Is Transforming Oncology by Ron Winslow

View here

John Hopkins University article

John Hopkins University And Compugen Team On Immune Checkpoints

View here

BioPortfolio article

Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform

View here

News pic

U.S. Approves Skin Cancer Treatment

Bristol-Myers’s Opdivo Is Latest Drug that Uses Immune  System to Fight Tumors

 View here

News HubFDA accepts Bristol-Myers’ sBLA for Opdivo + Yervoy in untreated melanoma

View here